|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's range||76.08 - 77.73|
|52-week range||64.27 - 89.54|
|PE ratio (TTM)||29.31|
|Earnings date||25 Jul 2018|
|Forward dividend & yield||2.28 (3.03%)|
|1y target est||86.00|
Kite, a Gilead Company (GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones.
Jim Cramer and technician Bob Lang inspect the charts to see if big-cap biotechnology stocks like Gilead and Celgene could have more room to run.
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
Gilead Sciences, Inc. (GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2018 and provide a general business update. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 8988927 to access the call.
Jim Cramer flies through his take on callers' favorite stocks, including an airline play feeling the heat.
Kite, a Gilead Company (GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access, and healthcare provider and patient services.
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Shares of Gilead Sciences (GILD) have edged up slightly this year, trailing the broader market, but first data from the biotech's rheumatoid arthritis drug filgotinib, potentially in the next couple weeks, should keep investors bullish on the shares, says Jefferies' Michael Yee. Yee writes that comparable efficacy and clean safety will be key factors that could differentiate the drug from the competition and provide a positive read-through for its other, separate Ulcerative Colitis study. Together, data for filgotinib, along with the drug selonsertib for nonalcoholic steatohepatitis, could help Gilead grow earnings per share and expand its price-to-earnings ratio toward 15 times, he writes.
Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.
Kite, a Gilead Company (GILD), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Authorization Application (MAA) for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel is a chimeric antigen receptor T cell (CAR T) therapy that modifies a patient’s own T cells to recognize and attack cancer cells and has the potential to induce complete responses (no detectable cancer) in a proportion of patients with aggressive forms of non-Hodgkin lymphoma (NHL).
The patent system allows prescription drug companies to hold unfair monopolies, promoting reckless pricing according to Tahir Amin.
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years. “To help support the long-term health of people living with HIV, it is crucial to have regimens that deliver durable viral suppression with a high barrier to resistance,” said Professor Alan Winston, Professor of HIV and Genitourinary Medicine at Imperial College and Consultant Physician at St. Mary’s Hospital, London, UK.
In this commentary, I will examine Gilead Sciences Inc’s (NASDAQ:GILD) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, asRead More...